VON WILLEBRAND DISEASE: DIAGNOSIS AND TREATMENT
Abstract
Background. Von Willebrand disease (VWD) is a most frequently inborn bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor (VWF). VWF promotes platelet-vessel wall (adhesion) and plateletplatelet interaction (aggregation). It is also the carrier for factor VIII (F VIII) in plasma. A deficiency of VWF may results in impairment of both, primary and secondary haemostasis. Therefore, patients with VWD can have bleeding symptoms typical fot the defect in primary haemostasis (mucocutaneous haemorrhages). In severe deficiency of VWF there are also haemarthroses and haematomas typical for patients with coagulation defects. Several types and subtypes of VWD have been described. The diagnosis is based on measurements of VWF concentration and activity and F VIII activity in plasma. The tests identifying VWD subtypes are ristocetin induced platelet agglutination (RIPA), multimeric analysis of VWF and measurement of the binding of VWF to F VIII.
Conclusions. Due to heterogeneity of VWF defects, the correct diagnosis of types and subtypes is sometimes difficult but is important for appropriate treatment. There are two main therapeutic options for patients with VWD: desmopressin and blood derived concentrates of F VIII/VWF. In certain cases antifibrinolytics and hormones can be suitable treatment. Desmopressin is the treatment of choice in patients with type 1 VWD. It raises endogenous F VIII and VWF and thereby corrects the intrinsic coagulation defect as well as the prolonged bleeding time (BT) or closure time (CT-PFA100) in most type 1 VWD patients. In type 3 and in the majority of type 2 patients desmopressin is not effective and it is necessary to use concentrates containing F VIII and VWF. These are always effective in raising of F VIII activity, whereas the BT/CT may not be completely corrected, but the normalisation of the BT/CT is not always necessary.
Downloads
References
Zimmerman TS, Ratnoff OD, Power AE. Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease. J Clin Invest 1971; 50: 244–54.
Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454–9.
Miller CH, Lenzi R, Breen C. Prevalence of VWD among US adults. Blood 1987; 70: Suppl 1: 377–83.
Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of VWD in children: a multiethnic study. J Pediatr 1993; 123: 893–8.
Rodeghiero F. Von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia 2002; 8: 292–300.
Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000; 108: 259–64.
Montgomery RR, Gill JC, Scott JP. Hemophilia and von Willebrand disease. In: Nathan DG, Orkin SH eds. Nathan and Oski’s Hematology of infancy and childhood. 5th ed. Vol. 2. Philadelphia: W.B.Saunders Company, 1998: 1631–59.
Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Prac Res Clin Hematol 2001; 14: 257–79.
Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998; 79: 456–65.
Federici AB, Castaman G, Mannucci PM, for the Italian association of hemophilia centers (AICE). Haemophilia 2002; 8: 607–21.
Page D. All about von Willebrand disease. Toronto: Canadian Hemophilia Society, 2000.
Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br J Haematol 1999; 106; 777–83.
Favaloro EJ. A duplex issue: (i) time to re-appraise the diagnosis and classification of von Willebrand disorder, and (ii) clarification of the roles of von Willebrand factor collagen binding and ristocetin cofactor activity assays. Haemophilia 2002; 8: 828–33.
Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease. Thromb Haemost 2000; 84: 1127–8.
Sadler JE. A revised classification of von Willebrand disease. Thromb Haemostas 1994; 563: 234–38.
Eikemboom JCJ, Reitsma PH, Peerlinck KMJ, Briet E. Recessive inheritance of von Willebrand disease type I. Lancet 1993; 341: 982–6.
Eikemboom JCJ, Castaman G, Vos HL et al. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost 1998; 79: 709–17.
Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90: 483–90.
Miller CH, Graham JB, Goldin LR, Elston RC. Genetics of classic von Willebrand’s disease I. Phenotypic variation within families. Blood 1979; 54: 117–36.
Orstavik KM, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89–101.
Nitu-Whalley IC, Lee CA, Griffioen A, Jenkins PV, Pasi KJ. Type 1 von Willebrand disease – a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history. Br J Haematol 2000;108: 259–64.
Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyzer using shear stress: a study of 60 cases. Blood 1998; 91: 1325–31.
Dean JA, Blanchette VS, Carcao MD et al. von Willebrand disease in a pediatric-based population-comparison of type 1 diagnostic criteria and use of the PFA-100R and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000; 84: 401–9.
Italian working group. Spectrum of von Willebrand’s disease: a study of 100 cases. Br J Haematol 1977: 35: 101–12.
Ciavarella G, Ciavarella N, Antoncecchi S et al. High-resolution analysis of von Willebrand factor multimeric composition defines a new variant of type I von Willebrand disease with aberant structure but presence of all size multimers (Type IC). Blood 1985; 66: 1423–9.
Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands disease (VWD) and discrimination of VWD subtypes, dependens on collagen source. Thromb Haemost 2000; 83: 127–35.
Asakura A, Harrison J, Gomperts EA et al. Type II A VWD with apparent recessive inheritance. Blood 1997; 69: 1419–20.
Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140–3.
Federici AB, Mannucci PM, Bader R et al. Heterogeneity in type II B vWD. Two unrelated cases with no family history and mild abnormalities of ristocetininduced interactions between vWF and platelets. Am J Hematol 1989; 23: 381–90.
Eikenboom JCJ, Castaman G, Kamphuisen PW, Rosendaal FR, Bertina RM. The FactorVIII/Von Willebrand factor ratio discriminates between reduced synthesis and increased clearence of vonWillebrand factor. Thromb Haemost 2002; 87: 252–7.
Ruggeri ZM, Pareti FI, Mannucci PM et al. Heightened interaction between platelets and factor VIII/vonWillebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med 1980; 302: 1047–51.
De Groot PG, Federici AB, De Boer HC et al. VWF synthesized by endothelial cells from a patient with type II B supports platelet adhesion normally but has an increased affinity for platelets. Proc Natl Acad Sci USA 1989; 86: 3793–7.
Rick ME, Williams SB, Sacher RA et al. Thrombocytopenia associated with pregnancy in a patient with type II B VWD. Blood 1987; 69: 786–9.
Pareti FI, Federici AB, Cattaneo M et al. Spontaneous platelet aggregation during pregnancy in a patient wtih vWD type II B can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. Br J Haematol 1990; 75: 86–91.
Federici AB. Diagnosis of von Willebrand disease. Haemophilia 1998; 4: 654–60.
Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160–74.
Federici AB, Mannucci PM. Advances in the genetics and reatment of von Willebrand disease. Current Opinion in Pediatrics 2002; 14: 23–33.
Favaloro EJ. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand’s disease. Blood Reviews 1999; 13; 185–204.
Kasper CK. Hereditary plasma clotting factor disorders and their management. The treatment of hemophilia. World Federation of Hemophilia 2000; 4: 1–19.
Shelton-Inloes BB, Chebab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletion correlates with the development of alloantibodies in von Willebrand disease. J Clin Invest 1987; 79: 1459–65.
Mannucci PM. Treatment of von Willebrand disease. Thromb Haemost 2001; 86: 149–53.
Holmberg L, Mannucci PM, Turesson I, Ruggeri ZM, Nilsson IM. Factor VIII antigen in the vessel walls in von Willebrand’s disease and haemophilia A. Scand J Haematol 1974; 13: 33–8.
Rinder MR, Richard RE, Rinder HM. Acquired von Willebrand’s disease: a concise review. Am J Haematol 1997; 54: 139–45.
Federici AB, Rand JH, Bucciarelli P et al. Acquired von Willebrand syndrome: data from an International Registry. Thromb Haemost 2000; 84: 345–9.
Federici AB, Mannucci PM. Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease. Haemophilia 1998; 4: Suppl. 3: 7–10.
Sutor AH. DDAVP is not a panacea for children with bleeding disorders. Br J Haematol 2000; 108: 217–27.
Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. Deamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand disease. Lancet 1977; 1: 869–72.
Mannucci PM, Bettega D, Cattaneo M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand disease and haemophilia A. Br J Haematol 1992; 82: 87–93
Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/ von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand disease. Br J Haematol 1981; 47: 283–93.
Lethagen S, Nilsson IM. DDAVP induced enhancement of platelet retention. Its dependance on platelet-von Willebrand factor and the platelet receptor GP IIb/IIIa. Eur J Haematol 1992; 49: 7–13.
Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders – the first twenty years. Blood 1997; 90: 2515–21.
Foster P. Von Willebrand disease. Current challenges in the care of hemophilia and von Willebrand disesae. Toronto: Canadian Hemophilia Society, 1997: 27–33.
Mentzer D, Burgsmüller G, Heller C, Andrischke K, Scharrer I, Kreuz W. Sufficient increase of clotting factors after reduced DDAVP test-dosage in von Willebrand’s disease type 1. Abstract. Thromb Haemost 1997; PS-2839: 696–6.
Jürgensen B, Merten HA, Wieding JU. DDAVP dose reduction to 0.2 mg/kg: Normalization of aspirin-induced bleeding tendency but reduction of adverse effects. Abstract. Ann Hematol 1998; 76: A33–3.
Lethagen S. Desmopressin (DDAVP). In: Forbes CD, Aledort L, Madhok R eds. Hemophilia. 1 st ed. London: Chapman and Hall Medical, 1997: 193–201.
Smith TJ, Gill JC, Ambruso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199–202.
Shepherd LL, Hutchinson RJ, Worden EK, Koopmann CF, Coran A. Hyponatremia and seizures after intravenous administration of desmopressin acetate for surgical hemostasis. J Pediatr 1989; 114: 470–2.
Weinstein RE, Bona RD, Altman AJ et al. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Haematol 1989; 32: 258–61.
Garcia EBG, Ruitenberg A, Madretsma GS, Hintzen RQ. Hyponatraemic coma induced by desmopressin and ibuprofen in a woman with von Willebrand’s disease. Haemophilia 2003; 9: 232–4.
Bond L, Bevin D. Myocardial infarction in a patient with hemophilia A treated with DDAVP. N Engl J Med 1988; 318: 121–1.
Mannucci PM, Bianchi A. Desmopressin, surgery and thrombosis. Thromb Haemost 1994; 71: 154–61.
Rodeghiero F, Castman G, Di Bona E, Ruggeri ZM. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand’s disease and hemophilia A. Blood 1997; 74: 1989–2000.
Cohen S, Daitch JS, Amar D, Goldiner PL. Epidural analgesia for labor and delivery in a patient with von Willebrand’s disease. Regional Anesthesia 1989; 14: 95–7.
Ruggeri ZM, Mannucci PM, Lombardi R, Federici AB, Zimmerman TS. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: Implications for patophysiology and therapy of von Willebrand’s disease subtypes. Blood 1982; 59: 1272–8.
Gralnick HR, Williams SB, McKeown LP et al. In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIA von Willebrand’s disease. Proc Natl Acad Sci USA 1985; 82: 5968–72.
Kunicki TJ, Montgomery RR, Schullek J. Cleavage of von Willebrand factor by platelet calcium-activated protease. Blood 1985; 65: 352–6.
Mannucci PM. Treatment of von Willebrand disease. Haemophilia 1998; 4: 661–4.
Castaman G, Rodeghiero F. Desmopressin and type IIB von Willebrand disease. Haemophilia 1996; 2: 73–7.
Mazurier C, Gaucher C, Jorieux S, Goudemand M and the Collaborative Group. Biological effect of desmopressin in eight patients with type 2N (»Normandy«) von Willebrand disease. Br J Haematol 1994; 88: 849–54.
Castaman G, Lattuada A, Mannucci PM et al. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br J Haematol 1995; 89: 849–54.
Berntrop E, Nilsson IM. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand’s disease. Vox Sang 1989; 56: 212–7.
Fricke WA, Yu MY. Characterization of von Willebrand factor in factor VIII concentrates. Am J Hematol 1989; 31: 41–5.
Mannucci PM, Tenconi P, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79: 3130–7.
Chang AC, Rick ME, Ross Pierce L, Weinstein MJ. Summary of a workshop on potency and dosage of von Willebrand factor concentrates. Haemophilia 1998; 4:Suppl 3: 1–6.
Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicentric study. Blood 2002; 99: 450–6.
Batlle J, Noya MS, Giangrande P, Lopez-Fernandez MF. Advances in the therapy of von Willebrand disease. Haemophilia 2002; 8: 301–7.
Federici AB, on behalf of the Steering Committee of the BH972256 European Study. Optimizing therapy of von Willebrand Disease with a safe and pure von Willebrand factor concentrate: the experience of the European Community. In: LFB Special Symposium of the XVIII Congress of the International Society of Thrombosis and Haemostasis 2001.
Mannucci PM. How I treat patients with von Willebrand’s disease. Blood 2001; 97: 1915–9.
Castillo R, Monteagudo J, Escolar G et al. Hemostatic effect of normal platelet transfusion in severe von Willebrand disease. Blood 1991; 77: 1901–5.
Castillo R, Escolar G, Monteagudo J, Aznar-Salatti J, Reverter JC, Ordinas A. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion 1987;37: 785–90.
Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostini A. Posttransfusion anaphylactic reaction in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125: 348–55.
Anon. Guidelines for the diagnosis and management of von Willebrand disease. Haemophilia 1997; 3: Suppl. 2: 4–8.
Meeting report. A meeting held in London, 12-13 January 1998, to discuss bleeding disorders in women. Haemophilia 1998; 4: 145–54.
Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. In: Aventis symposium ‘Von Willebrand factor: the new treatment paradigm’ of the XIX Congress of the International Society of Thrombosis and Haemostasis 2003; July: 12–8.
Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339: 245–53.
Mannucci PM. Treatment of von Willebrand disease. Haemophilia 1998; 4: 661–4.
Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid and tranexamic acid. BMJ 1996; 313: 579–82.
Ong YL, Hull DR, Mayne EE. Menorrhagia in von Willebrand disease successfully treated with a single daily dose tranexamic acid. Haemophilia 1998; 4: 63–5.
Kouides PA. Females with von Willebrand disease: 72 years as the silent majority. Haemophilia 1998; 4: 665–76.
Siegel JE, Kouides PA. Menorrhagia from a haemotologist’s point of view. Part II: management. Haemophilia 2002; 8: 339–47.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
